Publications

Increased vaccine sensitivity of an emerging SARS-CoV-2 variant.

Author(s): Lewnard JA, Hong V, Kim JS, Shaw SF, Lewin B, Takhar H, Lipsitch M, Tartof SY|Journal: Nat Commun|PMID: 37386005| June 2023

Host immune responses are a key source of selective pressure driving pathogen evolution. Emergence of many SARS-CoV-2 lineages has been…

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment – California, December 2021-May 2022.

Author(s): Malden DE, Hong V, Lewin BJ, Ackerson BK, Lipsitch M, Lewnard JA, Tartof SY|Journal: MMWR Morb Mortal Wkly Rep|PMID: 35737591| June 2022

Nirmatrelvir/ritonavir (Paxlovid) is a combination protease inhibitor that blocks replication of SARS-CoV-2 (the virus that causes COVID-19) and has been…

Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California.

Author(s): Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY|Journal: Nat Med|PMID: 35675841| June 2022

Epidemiologic surveillance has revealed decoupling of COVID-19 hospitalizations and deaths from case counts following emergence of the Omicron (B.1.1.529) SARS-CoV-2…

Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California

Author(s): Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY|Journal: medRxiv| January 2022

The Omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly achieved global dissemination, accounting for most infections in the United States by…